HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy.

Abstract
We studied the long-term outcome of patients with chronic hepatitis B virus (HBV) infection who responded to interferon (IFN) therapy. Between 1983 and 1988, 120 patients were included in 5 different protocols; 94 patients were treated with IFN and 26 were controls. Loss of serum HBV-DNA was considered a partial response and occurred in 34 of the treated patients and in 10 of the controls. Only the partial-response patients were followed up for 14-64 months (mean 46 months). HBeAg disappeared in 32/34 of the partial-response treated patients and in 9/10 of the controls. During the follow-up period, 6/34 (18%) treated patients and 1/10 controls suffered a reactivation of the disease with reappearance of HBV-DNA. Only 8/34 (23%) treated patients and 1/10 of the controls lost HBsAg; no statistical differences were observed in baseline characteristics between HBsAg-negative patients and patients who remained HBsAg-positive. Of eight HBsAg-negative treated patients, four were serum HBV-DNA-negative upon polymerase chain reaction and thus formed the HBsAg-negative control cases. Although the frequency of HBsAg loss in treated patients is relatively low, the improvement in liver disease obtained from IFN therapy is sustained over a long period.
AuthorsV Carreño, I Castillo, J Molina, J C Porres, J Bartolomé
JournalJournal of hepatology (J Hepatol) Vol. 15 Issue 1-2 Pg. 102-6 (May 1992) ISSN: 0168-8278 [Print] Netherlands
PMID1380526 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Interferons
Topics
  • Adolescent
  • Adult
  • Carrier State (blood, drug therapy, immunology)
  • DNA, Viral (analysis, genetics)
  • Female
  • Follow-Up Studies
  • Hepatitis B (blood, drug therapy, immunology)
  • Hepatitis B Surface Antigens (analysis)
  • Hepatitis B e Antigens (analysis)
  • Hepatitis B virus (genetics, immunology)
  • Humans
  • Interferons (therapeutic use)
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Radioimmunoassay
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: